Financing Research and Development

The Oxford Handbook of the Economics of the Biopharmaceutical Industry

Volumn , Issue , 2012, Pages

  Nicholson, Sean ^a,b,c  

^a Department of Obstetrics Gynecology   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

^c Upstate Health Research Network   (United States)

Author keywords

Biomedical spending; Biotech firms; Financial constraints; Market failures; Pharmaceutical firms; R D funding

Indexed keywords

EID: 85066516565     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/oxfordhb/9780199742998.013.0003     Document Type: Chapter

References (66)

1. Aghion, P., and J. Tirole. 1994. "On the Management of Innovation," Quarterly Journal of Economics 109: 1185-1207.
2. Akerlof, G.A. 1970. "The Market for 'Lemons': Quality Uncertainty and the Market Mechanism," The Quarterly Journal of Economics 84: 488-500.
3. Alti, A. 2003. "How Sensitive Is Investment to Cash Flow When Financing Is Frictionless?" Journal of Finance 58(2): 707-722.
4. Amit, R., L. Glosten, and E. Muller. 1990. "Entrepreneurial Ability, Venture Investments, and Risk Sharing." Management Science 36: 1232-1245.
5. Arora, A., A. Gambardella, F. Pammolli, and M. Riccaboni. 2000. The Nature and the Extent of the Market for Technology in Biopharmaceuticals. MPRA Paper 15977. University Library of Munich, Germany.
6. Arrow, K.J. 1963. "Uncertainty and the Welfare Economics of Medical Care." American Economic Review 53(5): 941-973.
7. Baumgardner, J.R. 1991. "The Interaction Between Forms of Insurance Contract and Types of Technical Change." RAND Journal of Economics 22(1): 36-53.
8. Bertoni, F., M.G. Colombo, and A. Croce. 2010. "The Effect of Venture Capital Financing on the Sensitivity to Cash Flow of Firm's Investments." European Financial Management 16(4): 528-551.
9. Bertrand, M., and S. Mullainathan. 2003. "Enjoying the Quiet Life? Corporate Governance and Managerial Preferences." Journal of Political Economy 111(5): 1043-1075.
10. Bertrand, M., and S. Mullainathan. 2005. Profitable Investments or Dissipated Cash? Evidence on the Investment-Cash Flow Relationship from Oil and Gas Lease Bidding. NBER Working Paper 11126. Cambridge, MA: National Bureau of Economic Research.
11. Biotechnology Industry Organization. 2009. Guide to Biotechnology 2008. Washington, DC: BIO.
12. Blanchard, O.J., F. Lopez-de-Silanes, and A. Schleifer. 1994. "What Do Firms Do With Cash Windfalls?" Journal of Financial Economics 36: 337-360.
13. Blume-Kohout, M. 2009. Drug Development and Public Research Funding: Evidence of Lagged Effects. Working paper, http://sites.google.com/site/mblumekohout/.
14. Campbell, T.S., and W.A. Kracaw. 1980. "Information Production, Market Signalling, and the Theory of Financial Intermediation." The Journal of Finance 35(4): 863-882.
15. Chan, Y. 1983. "On the Positive Role of Financial Intermediation in Allocation of Venture Capital in a Market with Imperfect Information." The Journal of Finance 38(5): 1543-1568.
16. Chemmanur, T.J. 1993. "The Pricing of Initial Public Offerings: A Dynamic Model With Information Production." The Journal of Finance 48(1): 285-304.
17. Chemmanur, T.J., and P. Fulghieri. 1994. "Investment Bank Reputation, Information Production, and Financial Intermediation," The Journal of Finance 49(1): 57-79.
18. Cockburn, I.M., and R.M. Henderson. 1998. "Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery." Journal of Industrial Economics 2:157-181.
19. Cutler, D.M. 2004. Your Money or Your Life: Strong Medicine for America's Health Care System. New York: Oxford University Press.
20. Danzon, P.M., S. Nicholson, and N. Sousa Pereira. 2005. "Productivity in Biotech-Pharmaceutical R&D: The Role of Experience and Alliances." Journal of Health Economics 24(2): 317-339.
21. Da Rin, M., and M.F. Penas. 2007. The Effect of Venture Capital on Innovation Strategies. NBER Working Paper 13636. Cambridge, MA: National Bureau of Economic Research.
22. DiMasi, J.A. 2001. "Risks in New Drug Development: Approval Success Rates for Investigational Drugs." Clinical Pharmacology & Therapeutics 69: 297-307.
23. Erickson, T., and T.M. Whited. 2000. "Measurement Error and the Relationship Between Investment and q." Journal of Political Economy 108(5): 1027-1057.
24. Ernst & Young. 2010. Beyond Borders: Global Biotechnology Report 2009. New York: Ernst & Young.
25. European Federation of Pharmaceutical Industries and Associations. 2009. The Pharmaceutical Industry in Figures: Key Data. Brussels, Belgium: EFPIA.
26. Fazzari, S., R.G. Hubbard, and B. Petersen. 1988. "Financing Constraints and Corporate Investment," Brookings Papers on Economic Activity 1: 141-195.
27. Garber, A.M., C.I. Jones, and P. Romer. 2006. "Insurance and Incentives for Medical Innovation." Forum for Health Economics & Policy 9(2): 1-25.
28. Giaccotto, C., R. Santerre, and J.A. Vernon. 2005. "Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry." Journal of Law & Economics 48(1): 195-214.
29. Gompers, P. 1995. "Optimal Investment, Monitoring, and the Staging of Venture Capital," Journal of Finance 50(4): 1461-1490.
30. Grabowski, H.G., and J.M. Vernon. 1981. "The Determinants of R&D Expenditures in the Pharmaceutical Industry." In Drugs and Health, ed. R. Helms. Washington, DC: American Enterprise Institute, 3-20.
31. Grabowski, H.G., and J.M. Vernon. 2000. "The Determinants of Pharmaceutical Research and Development Expenditures." Journal of Evolutionary Economics 10: 201-215.
32. Guedj, I. 2005. Ownership vs. Contract: How Vertical Integration Affects Investment Decisions in Pharmaceutical R&D. McCombs Research Paper Series FIN-01-06; AFA 2006 Boston Meetings Paper. Available at SSRN: http://ssrn.com/abstract=677371 (accessed November 2011).
33. Guedj, I., and D. Scharfstein. 2004. Organizational Scope and Investment: Evidence from the Drug Development Strategies and Performance of Biopharmaceutical Firms. NBER Working Paper 10933. Cambridge, MA: National Bureau of Economic Research.
34. Hall, B.H., and J. Lerner. 2009. The Financing of R&D and Innovation. NBER Working Paper 15325. Cambridge, MA: National Bureau of Economic Research.
35. Hellmann, T., and M. Puri. 2002. "Venture Capital and the Professionalization of Start-up Firms: Empirical Evidence." Journal of Finance 57: 169-197.
36. Higgins, M.J. 2007. "The Allocation of Control Rights in Pharmaceutical Alliances." Journal of Corporate Finance 13: 58-75.
37. Hsu, D. 2006. "Venture Capitalists and Cooperative Start-up Commercialization Strategy." Management Science 52(2): 204-219.
38. Hubbard, G. 1998. "Capital-Market Imperfections and Investment." Journal of Economic Literature 36: 193-225.
39. Jensen, M.C. 1986. "Agency Costs of Free Cash Flow, Corporate Finance, and Takeovers." American Economic Review 76: 323-329.
40. Jensen, M., and W. Meckling. 1976. "The Theory of the Firm: Managerial Behavior, Agency Costs, and Ownership Structure." Journal of Financial Economics 3: 305-360.
41. Jonsson, B., and N. Wilking. 2007. "The Burden and Cost of Cancer." Annals of Oncology 18(Supplement 3): 8-22.
42. Kaplan, S., and P. Stromberg. 2003. "Financial Contracting Theory Meets the Real World: An Empirical Analysis of Venture Capital Contracts." Review of Economic Studies 70: 281-315.
43. Kaplan, S.N., and L. Zingales. 1997. "Do Financing Constraints Explain Why Investment Is Correlated With Cash Flow?" Quarterly Journal of Economics 112: 168-216.
44. Kortum, S., and J. Lerner, J. 2000. "Assessing the Contribution of Venture Capital to Innovation." RAND Journal of Economics 31: 674-692.
45. Lamont, O. 1997. "Cash Flow and Investment: Evidence From Internal Capital Markets." The Journal of Finance 52(1): 83-109.
46. Leland, H.E., and D.H. Pyle. 1977. "Informational Asymmetries, Financial Structure, and Financial Intermediation." The Journal of Finance 32(2): 371-387.
47. Lerner, J. 1999. "The Government as Venture Capitalist: The Long-Run Impact of the SBIR Program." Journal of Business 72(3): 285-318.
48. Lerner, J., and U. Malmendier. 2010. "Contractibility and the Design of Research Agreements." American Economic Review 100(1): 214-246.
49. Lerner, J., and R.P. Merges. 1998. "The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry." The Journal of Industrial Economics 46(2): 125-156.
50. Lerner, J., H. Shane, and A. Tsai. 2003. "Do Equity Financing Cycles Matter? Evidence from Biotechnology Alliances." Journal of Financial Economics 64: 411-446.
51. Metrick, A., and S. Nicholson. 2009. "Does Financing Have Real Effects? Evidence From Drug Development." Working paper. Available at: http://www.human.cornell.edu/pam/people/upload/Finance:Jul_2009.pdf.
52. Moses, H., E.R. Dorsey, D.H.M. Matheson, and S.O. Thier. 2005. "Financial Anatomy of Biomedical Research." Journal of the American Medical Association 294(11): 1333-1342.
53. Newhouse, J.P. 1992. "Medical Care Costs: How Much Welfare Loss?" Journal of Economic Perspectives 6(3): 3-21.
54. Nicholson, S., P. Danzon, and J. McCullough. 2005. "Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality." Journal of Business 78(4): 1433-1464.
55. Pharmaceutical Research and Manufacturers of America. 2001. Pharmaceutical Industry Profile 2000. Washington, DC: PhRMA.
56. Pharmaceutical Research and Manufacturers of America. 2009. Pharmaceutical Industry Profile 2008. Washington, DC: PhRMA.
57. Pisano, G. 1997. R&D Performance, Collaborative Arrangements, and the Market-for-Know-How: A Test of the 'Lemons' Hypothesis in Biotechnology. Harvard Business School, Working Paper No. 97-105.
58. Powell, W.W., and P. Brantley. 1992. "Competitive Cooperation in Biotechnology: Learning Through Networks?" In Network and Organizations: Structure, Form and Action, ed. N. Nohria and R.G. Eccles, 366-394. Boston: Harvard Business School Press.
59. Powell, W.W., K.W. Koput, and L. Smith-Doerr. 1996. "Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology." Administrative Science Quarterly 41: 116-145.
60. Rauh, J.D. 2006. "Investment and Financing Constraints: Evidence from the Funding of Corporate Pension Plans." The Journal of Finance 61(1): 33-72.
61. Robinson, D.T., and T.E. Stuart. 2007. "Financial Contracting in Biotech Strategic Alliances." Journal of Law and Economics 50: 559-595.
62. Shin, H-H., and R.M. Stulz. 1998. "Are Internal Capital Markets Efficient?" Quarterly Journal of Economics 113: 531-553.
63. Stevens, A.J., J.J. Jensen, K. Wyller, P. Kilgore, S. Chatterjee, and M.L. Rohrbaugh. 2011. "The Role of Public-Sector Research in the Discovery of Drugs and Vaccines." The New England Journal of Medicine 364(6): 535-541.
64. Toole, A.A. 2007. "Does Public Scientific Research Complement Private Investment in Research and Development in the Pharmaceutical Industry." Journal of Law and Economics 50(1): 81-104.
65. Toole, A.A. 2008. The Impact of Public Basic Research on Industrial Innovation: Evidence from the Pharmaceutical Industry. SIEPR Discussion Paper 00-07, Stanford, CA: Stanford University.
66. Vernon, J.A. 2005. "Examining the Link Between Price Regulation and Pharmaceutical R&D Investment." Health Economics 14(1): 1-16.